Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases

Clinical Chemistry

Volumn 57, Issue 11, 2011, Pages 1534-1544

  Escudero, Jose M ^a   Auge, Jose M ^a   Filella, Xavier ^a   Torne, Aureli ^b   Pahisa, Jaume ^b   Molina, Rafael ^a  

^a Medical School   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CREATININE; HUMAN EPIDIDYMIS PROTEIN 4; TUMOR MARKER;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ASTHMA; BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ECZEMA; ENDOMETRIUM POLYP; FALSE POSITIVE RESULT; FEMALE; GYNECOLOGIC CANCER; HEPATITIS; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; OVARY CANCER; PEMPHIGUS; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN BLOOD LEVEL; PSORIASIS; PULMONARY HYPERTENSION; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; POSTMENOPAUSE; PREMENOPAUSE; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80055080310     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.157073     Document Type: Article

References (40)

1. Penson RT, Wenzel LB, Vergote I, Cella D. Quality of life considerations in gynecologic cancer. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S247-57.
2. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-66. (Pubitemid 38702089)
3. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15(Suppl 3): 274-81. (Pubitemid 43096594)
4. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79. (Pubitemid 352777353)
5. Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E, et al. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumour Biol 1992;13:278-86.
6. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267-77.
7. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
8. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-8. (Pubitemid 351174295)
9. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005;15:679-91. (Pubitemid 41783071)
10. How SH, Liam CK, Jamalludin AR, Chin SP, Zal AB. Serum cancer antigen 125 in patients with pleural effusions. Med J Malaysia 2006;61:558-63. (Pubitemid 46569502)
11. Molina R, Auge JM, Bosch X, Escudero JM, Vinolas N, Marrades R, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol 2009;30:121-9.
12. Bast RC, Jr., Knapp RC. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 1985;19: 354-6. (Pubitemid 15053583)
13. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991;37:1379-83. (Pubitemid 21925975)
14. Sevinc A, Camci C, Turk HM, Buyukberber S. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology 2003;65:1-6. (Pubitemid 36829084)
15. Trape J, Molina R, Sant F. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumour Biol 2004;25:276-81. (Pubitemid 40082331)
16. Anastasi E, Granato T, Marchei GG, Viggiani V, Colaprisca B, Comploj S, et al. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol 2010;31:411-5.
17. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010;203:228-6.
18. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117:440-5.
19. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700.
20. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19:847-53.
21. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002;21:2768-73. (Pubitemid 34478335)
22. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that isoverexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-9. (Pubitemid 40490123)
23. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96: 889-92.
24. Stephan C, Wesseling S, Schink T, Jung K. Comparison of eight computer programs for receiveroperating characteristic analysis. Clin Chem 2003;49:433-9. (Pubitemid 36250204)
25. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193:1630-9. (Pubitemid 41540458)
26. Bast RC Jr, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, et al. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol 1984;149:553-9. (Pubitemid 14086185)
27. Montagnana M, Lippi G, Danese E, Franchi M, Guidi GC. Usefulness of serum HE4 in endometriotic cysts. Br J Cancer 2009;101:548.
28. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem 1998;44: 1379-80. (Pubitemid 28309094)
29. van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, et al. Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up. Eur J Gynaecol Oncol 2009; 30:609-15.
30. Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol 2006;49: 433-47. (Pubitemid 44181417)
31. Hellstrom I, Heagerty PJ, Swisher EM, Liu P, Jaffar J, Agnew K, Hellstrom KE. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett 2010;296:43-8.
32. Molina R, Auge JM, Filella X, Vinolas N, Alicarte J, Domingo JM, Ballesta AM. Pro-gastrinreleasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res 2005;25:1773-8. (Pubitemid 40896801)
33. Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol 2008;622:15-21.
34. Molina R, Navarro J, Filella X, Castel T, Ballesta AM. S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 2002;23:39-44. (Pubitemid 34225020)
35. Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010;31:113-9.
36. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100: 1315-9.
37. Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 2009; 23:331-5.
38. Duk JM, Voorst Vader PC, Ten Hoor KA, Hollema H, Doeglas HM, de Bruijn HW. Elevated levels of squamous cell carcinoma antigen in patients with a benign disease of the skin. Cancer 1989;64: 1652-6. (Pubitemid 19251134)
39. Barcelo N, Ayllón O, Belmonte M, Barcelo A, Vidal R, Forteza-Rey J, Gutierrez A. Proposed reference value of the CA 125 tumour marker in men. Potential applications in clinical practice. Clin Biochem 2008;41:717-22.
40. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008; 110:196-201.